Geron (GERN) – Investment Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Geron (NASDAQ: GERN) recently:

• 1/10/2023 – Geron was upgraded by analysts at StockNews.com to a “sell” rating.
• 1/9/2023 – Geron had its price target raised by analysts at Needham & Company LLC from $3.00 to $4.00. They now have a “buy” rating on the stock.
• 1/9/2023 – Geron had its price target raised by analysts at B. Riley from $4.00 to $5.00.
• 1/4/2023 – Geron had its price target raised by analysts at Wedbush from $5.00 to $6.00. They now have an “outperform” rating on the stock.
• 12/27/2022 – Geron was upgraded by analysts at StockNews.com to a “sell” rating.
• 12/14/2022 – Geron was upgraded by analysts at StockNews.com to a “sell” rating.

Geron Price Performance

Shares of NASDAQ:GERN opened at $3.27 on Tuesday. Geron Co. has a 1-year low of $0.99 and a 1-year high of $3.84. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.68 and a quick ratio of 2.68. The business has a fifty day moving average price of $2.47 and a 200-day moving average price of $2.34. The company has a market capitalization of $1.25 billion, a PE ratio of -9.08 and a beta of 0.76.

Geron (NASDAQ:GERN – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Geron had a negative net margin of 8,563.80% and a negative return on equity of 110.76%. The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.12 million. As a group, equities analysts expect that Geron Co. will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Geron

Several institutional investors have recently modified their holdings of GERN. Mackenzie Financial Corp boosted its position in Geron by 154.3% in the second quarter. Mackenzie Financial Corp now owns 41,837 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 25,386 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Geron in the second quarter worth about $1,252,000. Bioimpact Capital LLC boosted its position in Geron by 37.2% in the second quarter. Bioimpact Capital LLC now owns 8,434,991 shares of the biopharmaceutical company’s stock worth $13,074,000 after purchasing an additional 2,285,714 shares during the last quarter. Matisse Capital purchased a new position in Geron in the second quarter worth about $124,000. Finally, Cambridge Investment Research Advisors Inc. boosted its position in Geron by 21.4% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 271,841 shares of the biopharmaceutical company’s stock worth $636,000 after purchasing an additional 48,000 shares during the last quarter. 49.75% of the stock is owned by hedge funds and other institutional investors.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.